2-(4-Isopropylphenyl)-2-methylpropan-1-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(4-Isopropylphenyl)-2-methylpropan-1-ol
• 英文别名: 2-methyl-2-(4-propan-2-ylphenyl)propan-1-ol
• 化学式: C₁₃H₂₀O
• mdl: MFCD00506632
• 分子量: 192.3
• InChiKey: VTASMXXAEGVHRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS
  申请人：Donde Yariv

  公开号：US20090270387A1

  公开（公告）日：2009-10-29

  Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.

  包含Y、A和B的化合物或其药用盐或前药的方法、组合物和药物也被揭示。
• [EN] AMIDE DERIVATIVES AS BTK INHIBITORS IN THE TREATMENT OF ALLERGIC, AUTOIMMUNE AND INFLAMMATORY DISORDERS AS WELL AS CANCER<br/>[FR] DÉRIVÉS AMIDES UTILISÉS COMME INHIBITEURS DE LA BTK DANS LE TRAITEMENT DES AFFECTIONS ALLERGIQUES, AUTO-IMMUNES ET INFLAMMATOIRES ET DANS LE TRAITEMENT DU CANCER
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010068806A1

  公开（公告）日：2010-06-17

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的化合物。描述了包括至少一种化合物I的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗对Btk活性和/或B细胞活性抑制敏感的患者的方法。描述了检测样本中Btk存在的方法。
• [EN] HETEROCYCLIC AMIDES AS BTK INHIBITORS<br/>[FR] AMIDES HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE LA BTK
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010068788A1

  公开（公告）日：2010-06-17

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的化合物。描述了包括至少一种化合物I的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗患有对Btk活性和/或B细胞活性抑制敏感的某些疾病的患者的方法。描述了检测样本中Btk存在的方法。
• [EN] PYRIDAZINONES AND THEIR USE AS BTK INHIBITORS<br/>[FR] PYRIDAZINONES ET LEUR UTILISATION COMME INHIBITEURS DE LA BTK
  申请人：CGI PHARMACEUTICALS INC

  公开号：WO2010056875A1

  公开（公告）日：2010-05-20

  Compounds of Formula (I) that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula (I), together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物(I)。描述了包含至少一种化合物(I)的药物组合物，以及至少一种从载体、辅料和赋形剂中选择的药用可接受载体。描述了治疗对Btk活性和/或B细胞活性抑制敏感的患者的方法。描述了检测样品中Btk存在的方法。
• [EN] SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES<br/>[FR] COMPOSÉS PURINES ET 7-DÉAZAPURINES SUBSTITUÉES EN TANT QUE MODULATEURS D'ENZYMES ÉPIGÉNIQUES
  申请人：EPIZYME INC

  公开号：WO2012075381A1

  公开（公告）日：2012-06-07

  The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOTl -mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

  本发明涉及替代嘌呤和7-去氮嘌呤化合物。本发明还涉及含有这些化合物的药物组合物以及通过向需要的受试者施用这些化合物和药物组合物来治疗DOT1介导的蛋白甲基化在内的疾病的方法，例如癌症和神经系统疾病。